Consider and approve the Audited Financial Results for the Financial Year ending 31st March, 2026, and recommendation of Final Dividend for the Financial Year 2025-26, subject to the approval ....
ANUHPHR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.2 pts less than Nifty Microcap 250 and 6.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Anuh Pharma reported FY2026 revenue of Rs. 77,166 lakhs, up 16.6% from Rs. 66,151 lakhs in FY2025. However, profit after tax fell 13.3% to Rs. 4,105 lakhs despite higher sales. EBITDA declined 6.1% to Rs. 6,608 lakhs, with margin compressing sharply from 10.64% to 8.56%. The company generated negative operating cash flow of Rs. 301 lakhs versus positive Rs. 3,712 lakhs last year, primarily due to a near doubling of inventory to Rs. 14,776 lakhs and rise in trade receivables. The board recommended a dividend of Rs. 1.50 per share (30% payout). Nine promoter group members holding 0.95% stake sought re-classification to public category. Auditors gave an unmodified (clean) opinion. The company issued bonus shares in 1:1 ratio in July 2025.
While revenue grew solidly, the sharp PAT decline, margin compression, and negative operating cash flow are concerning signals that may weigh on investor sentiment. The dividend offer provides some support. Promoter re-classification of less than 1% stake is minor.